Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals

Set Alert for Deals

Molnupiravir To Reach 105 LMICs Through MPP Agreement

Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.

Coronavirus COVID-19 Generic Drugs

Teva: $420m Securities Settlement In Our ‘Best Interest’

Teva has commented on its proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.

Companies Deals

Lupin Signs First Chinese Partnership With Foncoo

Lupin has partnered with Chinese firm Foncoo Pharmaceutical to begin supplying its portfolio of generic medicines to the region. At the same time, it has also acquired a number of brands from fellow Indian drug manufacturer Anglo-French Drugs & Industries Limited.

Deals M & A

Teva Agrees To $420m Securities Settlement For Alleged Price Fixing

Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.

Legal Issues Deals

Biocon Finalizes Merger Between Covidshield And Biologics Business

The merger between Serum Institute of India subsidiary Covidshield Technologies and Biocon Biologics has finally completed, subject to requisite approvals, after a Biocon board meeting.

M & A Deals

Hikma Buys Teligent Assets To Expand Into Canada

Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.

Deals Canada

Aurobindo’s CuraTeQ Expands Biosimilars Deal With Orion For Baltic Countries

Aurobindo’s CuraTeQ Biologics has expanded its biosimilar distribution agreement with Finnish Player Orion. After covering the Nordics, Austria, Hungary and Slovenia, the partnering companies have decided to expand to the Baltic countries, with launches slated for between 2023 and 2026.

Deals Biosimilars

FTC Gives Green Light To ANI-Novitium Acquisition Conditions

ANI is now firmly in the clear for its $210m acquisition of Novitium, following FTC approval of an order requiring divestiture of rights and assets to two generic products. The US-based firm is on an upward trajectory following its recent approval for Cortrophin Gel.

Deals Legal Issues

Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars

Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.

Biosimilars Pricing Strategies
See All
UsernamePublicRestriction

Register